Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation

Jan 13, 2010, 12:23 ET from Oxygen Biotherapeutics, Inc.

DURHAM, N.C., Jan. 13 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) chairman and CEO Chris Stern outlined plans for the introduction of new products during a presentation today at the OneMedForum 2010 investor conference in San Francisco.

During the brief presentation, limited by conference organizers to 10 minutes per company, Stern said Oxygen Biotherapeutics, Inc. plans to launch four products in its cosmetics line during 2010. They include an eye cream for fine line wrinkles around the eyes, a face lotion, an improved oxygen concentrate gel, and a perfluorocarbon skin oxygenating liquid -- all based on the company's perfluorocarbon oxygenating technology.

Stern also told the audience that the company has developed and plans to add two veterinary product lines based on Oxycyte™. Depending on regulatory approval, the first line could launch this year. It will feature topical wound treatment solutions. That would be followed by an intravenous veterinary product for multiple indications. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

The presentation was webcast live. A link to the replay will be posted on the company website.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine™. The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte™) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to plans to launch new products in the cosmetics and veterinary markets and the timing for such product launches. Actual events or results may differ from Oxygen Biotherapeutics, Inc.'s expectations. There can be no assurance that the products will reach the market in the estimated time period or at all. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SOURCE Oxygen Biotherapeutics, Inc.



RELATED LINKS

http://www.oxybiomed.com